{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T06:36:06Z","timestamp":1762756566265,"version":"build-2065373602"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017700","name":"Henan Provincial Science and Technology Research Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Although pediatric Burkitt lymphoma is considered curable, some patients still have a poor prognosis. Lack of early or complete response is an adverse prognostic factor. Therefore, improving patients\u2019 sensitivity to initial treatment and achieving complete remission early are crucial for enhancing efficacy. Herein, we report two cases of children with newly diagnosed clinical stage IV Burkitt lymphoma who achieved early complete metabolic remission after only two cycles of treatment with polatuzumab vedotin plus rituximab combined with chemotherapy. Notably, this represents the first reported application of polatuzumab vedotin in pediatric patients with newly diagnosed Burkitt lymphoma.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1684856","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T06:31:17Z","timestamp":1762756277000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Polatuzumab vedotin plus rituximab with chemotherapy in newly diagnosed pediatric stage IV Burkitt lymphoma: case report highlighting early complete remission"],"prefix":"10.3389","volume":"16","author":[{"given":"Yanyan","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunlei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenli","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.11.3370","article-title":"The societe francaise d\u2019oncologie pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with b-cell lymphomas and L3 leukemia","volume":"97","author":"Patte","year":"2001","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0973","article-title":"The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with b-cell neoplasms: a report of the BFM group study NHL-BFM95","volume":"105","author":"Woessmann","year":"2005","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036673","article-title":"Results of the randomized international FAB\/LMB96 trial for intermediate risk b-cell non-hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients","volume":"109","author":"Patte","year":"2007","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.3369","article-title":"Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (\u2265 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature b-cell non-hodgkin\u2019s lymphoma: results of the FAB LMB 96 study","volume":"30","author":"Cairo","year":"2012","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.09024.x","article-title":"Risk factors and treatment of childhood and adolescent burkitt lymphoma\/leukaemia","volume":"156","author":"Miles","year":"2012","journal-title":"Br J Haematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7534\/j.issn.1009-2137.2016.01.014","article-title":"Clinical and prognostic analysis of 43 children with mature b-cell non-hodgkin\u2019s lymphoma\/acute lymphoblastic leukemia","volume":"24","author":"Guo","year":"2016","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15491","article-title":"Overall survival of children and adolescents with mature b cell non-hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB\/LMB 96: a report from the FAB\/LMB 96 study group","volume":"182","author":"Cairo","year":"2018","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036665","article-title":"Results of a randomized international study of high-risk central nervous system b non-hodgkin lymphoma and b acute lymphoblastic leukemia in children and adolescents","volume":"109","author":"Cairo","year":"2007","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.255","article-title":"Rituximab and FAB\/LMB 96 chemotherapy in children with stage III\/IV b-cell non-hodgkin lymphoma: a children\u2019s oncology group report","volume":"27","author":"Goldman","year":"2013","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/bjh.13040","article-title":"Rituximab with chemotherapy in children and adolescents with central nervous system and\/or bone marrow-positive burkitt lymphoma\/leukaemia: a children\u2019s oncology group report","volume":"167","author":"Goldman","year":"2014","journal-title":"Br J Haematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature b-cell non-hodgkin\u2019s lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0578-1310.2018.08.010","article-title":"Clinical and prognostic analysis of 186 children with burkitt\u2019s lymphoma","volume":"56","author":"Zhang","year":"2018","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112140-20220429-00390","article-title":"Mid-term efficacy of China net childhood lymphoma-mature b-cell lymphoma 2017 regimen in the treatment of pediatric burkitt lymphoma","volume":"60","author":"Zhang","year":"2022","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14784","article-title":"Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin","volume":"176","author":"Li","year":"2019","journal-title":"Br J Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large b-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large b-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S394193","article-title":"Polatuzumab vedotin in a patient with refractory burkitt lymphoma, a case report","volume":"16","author":"Alanzi","year":"2023","journal-title":"Onco Targets Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2501018","article-title":"Glofitamab with polatuzumab vedotin in refractory Burkitt\u2019s lymphoma","volume":"392","author":"Prica","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1684856\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T06:31:42Z","timestamp":1762756302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1684856\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":18,"alternative-id":["10.3389\/fimmu.2025.1684856"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1684856","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"article-number":"1684856"}}